IP Library Granted Patent US 7,122,542
Granted Patent B2
US 7,122,542 · App. 10/903,870 · Granted Oct 17, 2006

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,122,542
App. No.
10/903,870
Granted
Oct 17, 2006
Kind
B2
Abstract

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Claims (6)

1. N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine and/or a pharmaceutically acceptable salt, hydrate, solvate and/or N-oxide thereof.

2. A pharmaceutical composition comprising N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine and/or a pharmaceutically acceptable salt, hydrate, solvate and/or N-oxide thereof.

3. A method of treating rheumatoid arthritis, comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine and/or a pharmaceutically acceptable salt, hydrate, solvate and/or N-oxide thereof.

4. The method of claim 3 in which the subject is a human.

5. A method of treating rheumatoid arthritis, comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of a pharmaceutical composition according to claim 2 .

6. The method of claim 5 in which the subject is a human.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2005
From: SINGH, RAJINDER; ARGADE, ANKUSH; LI, HUI; BHAMIDIPATI, SOMASEKHAR; CARROLL, DAVID; SYLVAIN, CATHERINE; CLOUGH, JEFFREY; KEIM, HOLGER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 015598/0954 →